# US 2021/0198274 A1 · Crystal Form Of Tenvermectin B, Preparation Method Therefor, And Use Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0198274 A1
- Document ID: US20210198274A1
- Status: Published application
- Kind: A1
- Application number: 17/057,869
- Filed: 2019-05-24
- Published: 2021-07-01
- Earliest claimed: 2018-05-28
- Assignees: Shenzhen Tenver Biopharm Co., Ltd.
- Applicants: Shenzhen Tenver Biopharm Co., Ltd.
- Inventors: Jidong Wang; Jiansong Li; Hui Zhang; Lingjian Zhang; Jun Huang
- Web page: https://patentgrep.com/patent/US20210198274A1

## CPC

- C07D 493/22: in which the condensed system contains four or more hetero rings
- C07H 1/06: Separation; Purification
- A01N 43/90: having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
- C07H 17/08: Hetero rings containing eight or more ring members, e.g. erythromycins
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- A01N: PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF (preservation of food or foodstuff A23); BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES (preparations for medical, dental or toiletry purposes which kill or prevent the growth or proliferation of unwanted organisms A61K); PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The present invention relates to a crystal form I of tenvermectin B, which can be characterized by X-ray powder diffraction (XRPD) pattern, Infrared (IR) absorption spectrum, Differential scanning calorimetry (DSC) thermogram and the like. Meanwhile, the present invention also relates to a method for preparing the crystal form I of tenvermectin B and a use thereof.

## Claims

### Claim 1

A crystal form I of tenvermectin B, wherein the crystal form I of tenvermectin B exhibits characteristic peaks at 2θ degree of 9.62±0.20°, 11.33±0.20°, 11.79±0.20°, 12.48±0.20°, 13.48±0.20°, 21.12±0.20° and 23.70±0.20° in X-ray powder diffraction pattern using Cu-Kα radiation.

### Claim 2 (depends on 1)

The crystal form I of tenvermectin B according to claim 1, wherein the crystal form I of tenvermectin B further exhibits characteristic peaks at 2θ degree of 6.71±0.20°, 9.22±0.20°, 12.02±0.20°, 14.95±0.20°, 17.39±0.20°, 18.33±0.20°, 22.97±0.20°, 26.53±0.20° and 27.16±0.20° in X-ray powder diffraction pattern using Cu-Kα radiation.

### Claim 3 (depends on 2)

The crystal form I of tenvermectin B according to claim 2, wherein the crystal form I of tenvermectin B further exhibits characteristic peaks at 2θ degree of 4.63±0.20°, 15.45±0.20°, 15.80±0.20°, 16.64±0.20°, 17.74±0.20°, 19.20±0.20°, 19.75±0.20°, 22.14±0.20°, 22.52±0.20°, 25.01±0.20°, 25.54±0.20° and 29.60±0.20° in X-ray powder diffraction pattern using Cu-Kα radiation.

### Claim 4 (depends on 1)

A method for preparing the crystal form I of tenvermectin B according to any one of claim 1, wherein the method comprises a step of precipitating the crystal form I of tenvermectin B from a solvent system containing formamide.

### Claim 5 (depends on 4)

The method according to claim 4, wherein the solvent system containing formamide is a combination of lower alcohol, formamide and water or a combination of lower ketone, formamide and water, wherein the lower alcohol is preferably selected from a group consisting of methanol, ethanol and isopropanol; and the lower ketone is preferably acetone.

### Claim 6 (depends on 4)

The method according to claim 4, wherein the solvent system containing formamide is a combination of ethanol, formamide and water.

### Claim 7 (depends on 4)

The method according to claim 4, wherein the method comprises steps of: dissolving tenvermectin B with ethanol, then adding formamide and water in sequence, stirring and crystallizing the thus obtained mixture to obtain the crystal form I of tenvermectin B.

### Claim 8 (depends on 7)

The method according to claim 7, wherein a ratio of the mass of the tenvermectin B to the volume of ethanol to the volume of formamide to the volume of water is 1 g:2 ml:4-5 ml:2 ml.

### Claim 9 (depends on 1)

A composition containing the crystal form I of tenvermectin B according to claim 1.

### Claim 10 (depends on 1)

A method for controlling parasites and harmful insects, comprising using effective amount of the crystal form I of tenvermectin B according to claim 1.

### Claim 11 (depends on 4)

The method according to claim 4, wherein the crystal form I of tenvermectin B further exhibits characteristic peaks at 2θ degree of 6.71±0.20°, 9.22±0.20°, 12.02±0.20°, 14.95±0.20°, 17.39±0.20°, 18.33±0.20°, 22.97±0.20°, 26.53±0.20° and 27.16±0.20° in X-ray powder diffraction pattern using Cu-Kα radiation.

### Claim 12 (depends on 4)

The method according to claim 4, wherein the crystal form I of tenvermectin B further exhibits characteristic peaks at 2θ degree of 4.63±0.20°, 15.45±0.20°, 15.80±0.20°, 16.64±0.20°, 17.74±0.20°, 19.20±0.20°, 19.75±0.20°, 22.14±0.20°, 22.52±0.20°, 25.01±0.20°, 25.54±0.20° and 29.60±0.20° in X-ray powder diffraction pattern using Cu-Kα radiation.

### Claim 13 (depends on 5)

The method according to claim 5, wherein the solvent system containing formamide is a combination of ethanol, formamide and water.

### Claim 14 (depends on 5)

The method according to claim 5, wherein the method comprises steps of: dissolving tenvermectin B with ethanol, then adding formamide and water in sequence, stirring and crystallizing the thus obtained mixture to obtain the crystal form I of tenvermectin B.

### Claim 15 (depends on 6)

The method according to claim 6, wherein the method comprises steps of: dissolving tenvermectin B with ethanol, then adding formamide and water in sequence, stirring and crystallizing the thus obtained mixture to obtain the crystal form I of tenvermectin B.

### Claim 16 (depends on 9)

The composition according to claim 9, wherein the crystal form I of tenvermectin B further exhibits characteristic peaks at 2θ degree of 6.71±0.20°, 9.22±0.20°, 12.02±0.20°, 14.95±0.20°, 17.39±0.20°, 18.33±0.20°, 22.97±0.20°, 26.53±0.20° and 27.16±0.20° in X-ray powder diffraction pattern using Cu-Kα radiation.

### Claim 17 (depends on 9)

The composition according to claim 9, wherein the crystal form I of tenvermectin B further exhibits characteristic peaks at 2θ degree of 4.63±0.20°, 15.45±0.20°, 15.80±0.20°, 16.64±0.20°, 17.74±0.20°, 19.20±0.20°, 19.75±0.20°, 22.14±0.20°, 22.52±0.20°, 25.01±0.20°, 25.54±0.20° and 29.60±0.20° in X-ray powder diffraction pattern using Cu-Kα radiation.

### Claim 18 (depends on 10)

The method according to claim 10, wherein the crystal form I of tenvermectin B further exhibits characteristic peaks at 2θ degree of 6.71±0.20°, 9.22±0.20°, 12.02±0.20°, 14.95±0.20°, 17.39±0.20°, 18.33±0.20°, 22.97±0.20°, 26.53±0.20° and 27.16±0.20° in X-ray powder diffraction pattern using Cu-Kα radiation.

### Claim 19 (depends on 10)

The method according to claim 10, wherein the crystal form I of tenvermectin B further exhibits characteristic peaks at 2θ degree of 4.63±0.20°, 15.45±0.20°, 15.80±0.20°, 16.64±0.20°, 17.74±0.20°, 19.20±0.20°, 19.75±0.20°, 22.14±0.20°, 22.52±0.20°, 25.01±0.20°, 25.54±0.20° and 29.60±0.20° in X-ray powder diffraction pattern using Cu-Kα radiation.
